We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) – Leerink Partnrs issued their Q1 2025 earnings estimates for shares of BridgeBio Pharma in a research note issued on Monday, February 24th.

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against other best performing pharma stocks so far in 2025. On February 20, Jared Holz ...

Citi raised the firm’s price target on BridgeBio (BBIO) to $49 from $45 and keeps a Buy rating on the shares following the Q4 report. As of ...

BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...

BridgeBio Pharma Inc (NASDAQ:BBIO) is set to release its Q4 2024 earnings on Feb 20, 2025. The consensus estimate for Q4 2024 ...

BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results on Thursday, February 20th. The company reported earnings of -$1.31 per share, missing estimates of -$1.15 ...